Cesca Therapeutics 

0
0
+€0.00+0% 00:00 今天

統計

當日最高
-
當日最低
-
52週高點
-
52週低點
-
成交量
-
平均成交量
-
市值
0
本益比
-
股息殖利率
-
股息
-

財報

1Jan預期
Q4 0
0.02
0.36
0.69
1.02
預期EPS
0.022764
實際EPS
不適用

財務

-189.82%利潤率
未盈利
2018
2019
2020
2021
2022
2023
8.7M營收
-16.51M淨利

其他人也在關注

此清單是根據在 Stock Events 上追蹤 THRN.MU 的使用者自選建立的。這不是投資建議。

競爭對手

此清單為基於近期市場事件的分析。並非投資建議。

關於

ThermoGenesis Holdings, Inc., founded in 1986 and based in Rancho Cordova, California, is a global innovator specializing in automated systems for cell-banking, cell-processing, and cell-based therapeutic applications. The company's advanced solutions are available across the United States, China, the United Arab Emirates, Vietnam, and other international regions. Its product portfolio encompasses medical devices crucial for automated cell processing. For clinical bio-banking purposes, ThermoGenesis provides the AXP II Automated Cell Separation System, a fully closed system designed for isolating stem and progenitor cells from umbilical cord blood. Complementing this is the BioArchive Automated Cryopreservation System, a robotic, liquid nitrogen-controlled system for both freezing and long-term cryogenic storage of cord blood samples and cell therapeutic products used in clinical environments. In the realm of point-of-care applications, the company offers the XP Point-of-Care System, an automated, sterile, and closed platform that facilitates the rapid processing of autologous stem cells derived from peripheral blood or bone marrow aspirate directly within clinical settings such as surgical centers. Additionally, the PXP-1000 System is another automated, closed solution, engineered for fast and reproducible separation of multiple cellular components from blood with minimal red blood cell contamination. For general laboratory use, ThermoGenesis provides its X-Series cell processing products, including X-Lab for cell isolation, the X-Wash System for efficient cell washing and reformulation, and X-Mini for high-efficiency, small-scale cell purification. Beyond its product offerings, the company also delivers contract development and manufacturing (CDMO) services specifically for cell and cell-based gene therapies. Its medical device products are marketed and sold through a network of independent distributors, as well as directly to end-user customers. The company, formerly known as Cesca Therapeutics Inc., officially adopted the name ThermoGenesis Holdings, Inc. in November 2019.
Show more...
執行長
Dr. Xiaochun Xu M.B.A., Ph.D.
員工
25
國家
美國
ISIN
US1571313014

上市

0 Comments

分享你的想法

FAQ

Cesca Therapeutics 的股票代號是什麼?
根據交易所不同,股票代號可能會有所差異。例如,在 Boerse Muenchen 交易所,Cesca Therapeutics 的股票以代號 THRN.MU 進行交易。
Cesca Therapeutics 去年的營收是多少?
Cesca Therapeutics 去年的營收為 8.7MEUR。
Cesca Therapeutics 去年的淨利是多少?
THRN.MU 去年的淨收益為 -16.51MEUR。
Cesca Therapeutics 有多少名員工?
截至 July 22, 2026,公司共有 25 名員工。
Cesca Therapeutics 位於哪個產業?
Cesca Therapeutics從事於Health & Wellness產業。
Cesca Therapeutics 何時完成拆股?
Cesca Therapeutics 最近沒有進行任何拆股。
Cesca Therapeutics 的總部在哪裡?
Cesca Therapeutics 的總部位於 美國 的 Rancho Cordova。